A GLP-1 / GCG / FGF21 multi-agonist fusion protein, its preparation method and application
By designing a GLP-1/GCG/FGF21 multi-agonist fusion protein, integrating the multiple agonist activities of GLP-1/GCG/FGF21 and prolonging the half-life, the efficacy of existing drugs in MASH treatment and the stability problem of FGF21 are solved, achieving multi-dimensional therapeutic effects for metabolic diseases.
Patent Information
- Application Number
- CN202611136131.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-29
- Publication Date
- 2026-11-17
AI Technical Summary
Existing drugs have limited efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH), especially in improving liver fibrosis. Furthermore, FGF21 analogs suffer from poor in vitro stability, easy aggregation, and short in vivo half-life. Therefore, there is a need to develop treatment regimens that combine multiple agonist activities of GLP-1/GCG/FGF21.
A GLP-1/GCG/FGF21 multiple agonist fusion protein was designed by integrating GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity into the same molecule, using a long-acting domain B to extend the half-life, and expressing it through gene recombination to avoid chemical modification.
It significantly reduces body weight, liver weight, and liver-to-body ratio; lowers plasma ALT, AST, CHOL, and LDL-C levels, as well as liver CHOL and TG content; improves liver NAS scores; provides comprehensive treatment for metabolic-related diseases; reduces immunogenicity risks; simplifies manufacturing processes; and improves product quality stability.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, specifically to a GLP-1 / GCG / FGF21 multiple agonist fusion protein, its preparation method, and its applications. Background Technology
[0002] Metabolic dysfunction-associated fatty liver disease (MAFLD) is a group of diseases characterized by excessive fat accumulation in the liver. Fatty liver is defined as a liver fat content exceeding 5%. As the disease progresses, the liver becomes inflamed and accompanied by varying degrees of fibrosis or scarring, entering the metabolic dysfunction-associated steatohepatitis (MASH) stage. If not effectively controlled, long-term MASH can progress to cirrhosis and lead to serious complications such as liver failure and hepatocellular carcinoma. Common risk factors for MAFLD include overweight, metabolic syndrome, insulin resistance, hyperglycemia, and hypercholesterolemia.
[0003] MAFLD has a global prevalence of approximately 30%, making it a significant public health issue. Of MAFLD patients, about 5.27% further develop MASH. Without intervention, liver fibrosis worsens by one grade every 7 years on average, with a significantly increased risk of death when it progresses to moderate to severe fibrosis (F3 or F4 stage). Furthermore, MAFLD is frequently associated with obesity (51%–81%), cardiovascular disease (20%–50%), and type 2 diabetes (22%–43%), further exacerbating the disease burden.
[0004] Currently, treatment for MASH primarily includes lifestyle interventions, bariatric surgery, and medication. Regarding medication, existing technologies include GLP-1 receptor agonists (liraglutide, smegglutide, telpoxetine), thiazolidinediones (pioglitazone), and SGLT-2 inhibitors for metabolic improvement in MASH patients. To date, only two drugs have received accelerated approval from the FDA for the treatment of F2 to F3 stage MASH patients: the thyroid hormone receptor-β (THR-β) agonist Resmetirom (MGL-3196) and the GLP-1 receptor agonist smegglutide (Wegovy). However, the clinical efficacy of these drugs is limited, particularly in improving liver fibrosis, making it difficult to meet the clinical needs of patients with severe MASH, necessitating the development of more effective treatment options.
[0005] GLP-1 is a 37-amino acid incretin secreted by intestinal L cells. It stimulates insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces food intake, exhibiting good hypoglycemic and weight-loss effects, and also has a certain protective effect on the liver. GCG (glucagon) is a 29-amino acid linear polypeptide secreted by pancreatic α cells. Activation of the glucagon receptor (GCGR) increases energy expenditure and promotes lipolysis, thereby enhancing weight loss and helping to improve hepatic lipid metabolism. The combined use of GLP-1 receptor agonists and GCG receptor agonists can have an additive effect on weight loss and improved liver metabolism. Studies have reported the design and application of chimeric peptides with dual GLP-1 and GCG receptor agonist activities, confirming the feasibility of the GLP-1 / GCG dual-target strategy.
[0006] FGF21 (fibroblast growth factor 21) is a member of the FGF family, containing 181 amino acids. It promotes glucose uptake by adipocytes, enhances insulin sensitivity, and reduces serum total cholesterol and low-density lipoprotein levels, exhibiting multiple functions in metabolic regulation and liver protection. In vitro and in vivo studies have shown that FGF21 receptor agonists can effectively alleviate MASH scores and liver fibrosis, especially for patients in stages F3 to F4, demonstrating significant therapeutic value and broad clinical application prospects. However, natural FGF21 has significant limitations: poor in vitro stability, easy aggregation, and susceptibility to protease hydrolysis, along with an extremely short in vivo half-life (approximately 30 minutes in mice and 2 to 3 hours in cynomolgus monkeys), severely restricting its clinical application. To overcome these shortcomings, various FGF21 modification strategies have been reported, including fusing FGF21 with IgG Fc sequences, coupling with fatty acid chains or polyethylene glycol (PEG), and site-directed mutagenesis of enzyme cleavage sites and aggregation-related amino acids to prolong the in vivo half-life and improve stability.
[0007] Based on clinical data from marketed and investigational drugs, single-target therapies still have significant limitations in the treatment of MASH: GLP-1 receptor agonists have limited efficacy in improving liver fibrosis; and FGF21 analogs are also less effective than GLP-1 receptor agonists in weight loss and blood glucose control. Therefore, there is a need in this field to develop a multi-domain active protein that possesses multiple agonist activities (GLP-1 / GCG / FGF21) and can effectively improve metabolic dysfunction-related steatohepatitis, obesity, and related glucose and lipid metabolism disorders, providing a more comprehensive treatment option for MASH patients and those with associated metabolic diseases. Summary of the Invention
[0008] In view of the shortcomings of the prior art described above, the purpose of this invention is to provide a GLP-1 / GCG / FGF21 multiple agonist fusion protein, its preparation method and application. By fusing and expressing a first active domain A with GLP-1 receptor agonist activity and a long-acting domain B with GCG receptor agonist activity and a second active domain C with FGF21 receptor complex agonist activity, the resulting fusion protein possesses multiple agonist functions of GLP-1 / GCG / FGF21 in the same molecule, thereby enabling its use in the prevention and / or treatment of metabolic-related diseases.
[0009] To achieve the above objectives, the present invention provides the following technical solution:
[0010] The first aspect of the present invention provides a fusion protein, which simultaneously possesses GLP-1 receptor agonist activity, GCG receptor agonist activity and FGF21 receptor complex agonist activity, and the fusion protein comprises a first active domain A, a first linker peptide L1, an extended-acting domain B, a second linker peptide L2 and a second active domain C connected sequentially from the N-terminus to the C-terminus.
[0011] Wherein, the first active domain A is a chimeric peptide with GLP-1 receptor agonist activity and GCG receptor agonist activity, and the amino acid sequence of the first active domain A is selected from any one of SEQ ID NO.12 to SEQ ID NO.15; the extended domain B contains the immunoglobulin Fc region or a fragment thereof, or a mutant thereof; the second active domain C is FGF21 or an analogue thereof, wherein FGF21 is human FGF21, the amino acid sequence of the FGF21 analogue has greater than or equal to 80% identity with the amino acid sequence of human FGF21, and has FGF21 receptor complex agonist activity.
[0012] In some embodiments, the extended-acting domain B is selected from the complete Fc sequence, partial Fc sequence, or mutant of mammalian IgG1, IgG2, IgG3, or IgG4; the amino acid sequence of the extended-acting domain B is shown in SEQ ID NO.23 or SEQ ID NO.24.
[0013] In some embodiments, the amino acid sequence of the FGF21 is shown in SEQ ID NO. 68; preferably, the FGF21 analogue includes one or more of the following mutations relative to the human FGF21 amino acid sequence shown in SEQ ID NO. 68: R19V, L98R, L146P, S167H, P171A, P171G, R175L, and A180E.
[0014] In some embodiments, the amino acid sequence of the FGF21 analog comprises any of the following sets of mutations relative to the human FGF21 amino acid sequence shown in SEQ ID NO. 68:
[0015] a) R19V, L98R, P171G, and A180E;
[0016] b) R19V, L98R, S167H, P171A and R175L;
[0017] c) R19V, L98R, L146P, P171G and A180E;
[0018] d) R19V, L98R, S167H, P171A and A180E;
[0019] e) L98R, L146P, P171G and A180E.
[0020] In some embodiments, the amino acid sequence of the FGF21 analog is shown in SEQ ID NO.25 or SEQ ID NO.69; and / or, the amino acid sequence of the first linker peptide L1 and the amino acid sequence of the second linker peptide L2 are both shown in SEQ ID NO.22.
[0021] In some embodiments, the amino acid sequence of the first active domain A is shown in SEQ ID NO.14, and the amino acid sequence of the extended domain B is shown in SEQ ID NO.24.
[0022] In some embodiments, the amino acid sequence of the fusion protein is as shown in any one of SEQ ID NO.37 to SEQ ID NO.40 or SEQ ID NO.70.
[0023] In some embodiments, the fusion protein exists in monomeric and / or polymeric forms, wherein the polymeric form is selected from one or more of dimers, trimers, or polymers with a degree of polymerization greater than four. Preferably, the dimer is a homodimer mediated by the Fc region carried by the extended-acting domain B.
[0024] In some embodiments, the fusion protein is a modified fusion protein; preferably, the modification is selected from one or more of glycosylation, phosphorylation, acetylation, amidation, esterification, polyethylene glycolation, and disulfide bond formation.
[0025] This application also provides a biomaterial, said biomaterial being selected from any of the following:
[0026] 1) An isolated polynucleotide, said polynucleotide comprising a nucleotide sequence encoding the fusion protein described in the first aspect above;
[0027] 2) A recombinant expression vector comprising the polynucleotide described in 1); preferably, the recombinant expression vector further comprises a nucleotide sequence of a tag for assisting expression and / or purification; more preferably, the tag is a SUMO tag;
[0028] 3) Host cell, wherein the host cell contains the polynucleotide described in 1) or the recombinant expression vector described in 2); preferably, the host cell is selected from Escherichia coli cells, CHO cells, HEK293 cells or yeast cells.
[0029] This application also provides the use of the above-mentioned biomaterials in the preparation of the above-mentioned fusion protein.
[0030] This application also provides a composition comprising the above-described fusion protein or biological material. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the pharmaceutical composition further comprises pharmaceutically acceptable excipients.
[0031] This application also provides the application of the above-described fusion protein, or the above-described biomaterial, or the above-described composition, wherein the application is for the preparation of a medicament for the prevention and / or treatment of metabolic-related diseases. Preferably, the metabolic-related diseases include metabolic dysfunction-related steatohepatitis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, obesity, overweight, type 2 diabetes, hyperlipidemia, hypercholesterolemia, insulin resistance, metabolic syndrome, liver dysfunction, hepatic lipid accumulation, or liver fibrosis.
[0032] This application also provides a method for preparing the above-mentioned fusion protein, comprising the following steps:
[0033] S1. Cultivate the host cells described in the above-mentioned biological materials, and express the above-mentioned fusion protein in the host cells, or express a fusion precursor protein containing the above-mentioned fusion protein and a tag;
[0034] S2. Isolate and purify the fusion protein from the culture of the host cells;
[0035] When expressing the fusion precursor protein, the separation and purification includes removing the tag to obtain the fusion protein.
[0036] This application also provides a method for treating metabolic-related diseases, characterized by administering a therapeutically effective amount of the above-mentioned fusion protein or biological material, or the above-mentioned composition, to a subject in need; preferably, the metabolic-related disease is selected from one or more of the following diseases: metabolic dysfunction-related steatohepatitis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, obesity, overweight, type 2 diabetes, hyperlipidemia, hypercholesterolemia, insulin resistance, metabolic syndrome, liver dysfunction, hepatic lipid accumulation, and liver fibrosis; more preferably, the metabolic-related disease is metabolic dysfunction-related steatohepatitis.
[0037] This application also provides a fusion protein, biomaterial, or composition described in this invention for use as a drug.
[0038] This application also provides a fusion protein, biomaterial, or composition according to the present invention for the prevention and / or treatment of diseases.
[0039] This application also provides the fusion proteins, biomaterials, or compositions described herein for the prevention and / or treatment of metabolic-related diseases.
[0040] As described above, the present invention has the following beneficial effects:
[0041] 1. This invention integrates a first active domain A with GLP-1 receptor agonist activity and a long-acting domain B with GCG receptor agonist activity, and a second active domain C with FGF21 receptor complex agonist activity into the same fusion protein molecule. This allows the fusion protein to simultaneously possess GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity within a single molecule. Compared to existing drugs with only single or dual receptor agonist activity, this invention can synergistically exert therapeutic effects from multiple dimensions, including metabolic improvement, weight loss and lipid reduction, and liver anti-inflammatory and anti-fibrotic effects, providing a more comprehensive treatment plan for metabolic disorders such as metabolic dysfunction-related steatohepatitis. In vivo pharmacodynamic experiments of the fusion protein (3G4-10) described in this invention in the B6-Alms1-del mouse MASH model showed that the fusion protein can significantly reduce body weight, liver weight and liver-to-body ratio, significantly reduce plasma ALT, AST, CHOL, LDL-C levels and liver CHOL and TG content, and significantly improve liver NAS score (steatodegenesis, hepatocyte ballooning degeneration). Moreover, most of the pharmacodynamic indicators are better than single-target positive control drugs, which confirms the therapeutic advantages of the fusion protein provided by this invention compared with existing single-target drugs.
[0042] 2. The fusion protein of this invention, by introducing a long-acting domain B, can utilize the binding of the Fc region to the neonatal Fc receptor (FcRn) to mediate intracellular reuse of the fusion protein, thereby prolonging its in vivo half-life, reducing the frequency of clinical dosing, and improving patient compliance. Furthermore, addressing the inherent defects of natural FGF21, such as poor in vitro stability, easy aggregation, susceptibility to protease hydrolysis, and short in vivo half-life, this invention optimizes the FGF21 amino acid sequence through combinatorial mutations at specific sites. This yields an FGF21 analog that significantly improves the purity of the target protein expression in mammalian cell expression systems while retaining or even enhancing the agonistic activity of the FGF21 receptor complex, thus improving the manufacturability and druggability of the fusion protein of this invention. All domains in the fusion protein of this invention are derived from human protein sequences (human GLP-1 / GCG chimeric peptide, human immunoglobulin Fc region, human FGF21 analog), and compared to long-acting protein drugs obtained through chemical modification (such as coupling with fatty acid chains, polyethylene glycol, etc.), it is expected to have a lower risk of immunogenicity.
[0043] 3. The fusion protein described in this invention can be obtained by gene recombination in prokaryotic or eukaryotic host cells without relying on high-cost chemical synthesis or chemical modification processes, which helps to reduce production costs, simplify production processes, and improve batch stability of product quality. Attached Figure Description
[0044] Figure 1 The results of SDS-PAGE analysis of the expression of the fusion precursor protein during the fermentation of the recombinant engineered bacteria 3G4-4F-pET28a-BL21(DE3) in Example 2 of this application are shown.
[0045] Figure 2 The results are SDS-PAGE analysis of purified fusion proteins from Example 3 of this application, including fusion proteins 21G2-4F, 22G1-4F, 3G3-4F, and 3G4-4F.
[0046] Figure 3 The figures show the in vitro receptor agonist activity detection results of different batches of fusion proteins 3G1-4F, 3G2-4F, 3G3-4F, 3G4-4F and 3G5-4F in Example 4 of this application; the error bars in the figures show the stability of the in vitro receptor agonist activity among different batches of samples.
[0047] Figure 4 The results show the transient expression of fusion proteins 3G4-1 to 3G4-9 in CHO-K1 cells in Example 5 of this application.
[0048] Figure 5The results show the transient expression of fusion proteins 3G4-10, 2G5-1, 2G5-2 and 3G4-F1 to 3G4-F5 in CHO-K1 cells in Example 5 of this application.
[0049] Figure 6 The results show the transient expression of the fusion proteins 3G4-4F, 3G4-D1 to 3G4-D3, and two negative control molecules in CHO-K1 cells in Example 5 of this application.
[0050] Figure 7 This describes the weight loss effect of the 3G4-10 fusion protein in Example 6 of this application in the B6-Alms1-del mouse MASH model.
[0051] Figure 8 This demonstrates the effect of the 3G4-10 fusion protein in Example 6 of this application on reducing liver cholesterol and triglyceride levels in the B6-Alms1-del mouse MASH model.
[0052] Figure 9 This study demonstrates the effect of the 3G4-10 fusion protein in Example 6 of this application on improving plasma biochemical parameters in the B6-Alms1-del mouse MASH model.
[0053] Figure 10 This application describes the effect of the 3G4-10 fusion protein in Example 6 of this application on improving steatosis and hepatocellular ballooning degeneration in the liver NAS score in the B6-Alms1-del mouse MASH model. Detailed Implementation
[0054] To make the inventive purpose, technical solution and beneficial effects of this application clearer, the following description is provided in conjunction with embodiments.
[0055] Unless the context clearly indicates otherwise, the singular forms “a,” “an,” “the,” and “the” used herein include the plural forms as well; conversely, the plural forms include the singular forms. The terms “comprising,” “including,” “containing,” “having,” and similar expressions used herein are open-ended terms, indicating that they may also include or contain other components, steps, structures, conditions, or parameters not explicitly listed. Content expressed as a numerical range herein should be understood to include both endpoints of the range as well as any specific numerical value or any subrange within the range.
[0056] Unless otherwise stated, all reagents, materials, cells, plasmids, culture media, instruments, and equipment used in the embodiments of this application are commercially available or can be prepared or obtained according to conventional methods in the art. Unless otherwise stated, steps in the embodiments of this application that do not specify specific experimental conditions can be performed according to conventional conditions in the art, manufacturer's instructions, or conditions that can be reasonably determined by those skilled in the art based on the experimental purpose. For reagents or materials whose source is not specified, conventional reagents or materials in the art that can achieve the same or similar functions can be used as substitutes.
[0057] In this application, unless the context explicitly specifies otherwise, when referring to the names of genes, nucleic acids, proteins, polypeptides, receptors, or corresponding biomolecules, the same or similar names or abbreviations are sometimes used, and those skilled in the art can determine their specific meaning based on the context. For example, a name may refer to the gene or nucleic acid sequence encoding the protein, or it may refer to the protein, polypeptide, or receptor molecule expressed by the gene or nucleic acid sequence. Unless otherwise defined, the technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which this application pertains.
[0058] Unless the context clearly indicates otherwise, the terms "about" or "approximately" as used herein mean that the relevant values may be subject to measurement or experimental errors generally permissible in the art. In some embodiments, "about" indicates a deviation of no more than ±10%, ±5%, ±2%, or ±1% relative to the listed value. For values that are required to be integers, such as the number of amino acid residues, the number of doses, or the number of animals, they should be understood as the corresponding integers in the context.
[0059] In this application, the terms "protein" and "peptide" are used interchangeably, both referring to molecules formed by amino acid residues linked by peptide bonds, and may include post-translational modifications, chemical modifications, disulfide bonds, or other modifications that do not alter their basic amino acid backbone.
[0060] In this application, the terms "polynucleotide" and "nucleic acid" are used interchangeably to refer to polymers formed by the linkage of nucleotides, including DNA, RNA, and combinations thereof, and can be single-stranded or double-stranded, linear or circular, of natural origin or artificially synthesized. Due to the degeneracy of the genetic code, polynucleotides encoding the same fusion protein can have different nucleotide sequences.
[0061] The term "fusion protein" refers to a protein formed by the direct linking or linkage of two or more proteins, polypeptides, peptides, or their domains from the same or different sources and having the same or different structures or functions. Unless otherwise stated, the fusion protein may be expressed as a continuous polypeptide chain and may further form monomers, dimers, trimers, tetramers, or other multimers. The terms "multi-domain active protein," "multi-domain fusion protein," and "fusion protein" used in this application are interchangeable and all refer to proteins containing a first active domain A, a long-acting domain B, and a second active domain C, and possessing GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity.
[0062] The term "connecting peptide" refers to a peptide sequence that connects two adjacent proteins, polypeptides, or domains. Connecting peptides can be flexible, semi-flexible, or rigid.
[0063] The terms "analyte," "variant," or "mutant" refer to a protein or polypeptide obtained by substituting, deleting, and / or adding one or more amino acids based on the amino acid sequence of a corresponding reference protein or polypeptide, while retaining at least one target biological activity of the corresponding reference protein or polypeptide. The amino acid substitutions, deletions, and / or additions may be located at the N-terminus, C-terminus, or internal region of the protein or polypeptide.
[0064] The term "identity" or "sequence identity" refers to the degree to which two amino acid sequences or nucleotide sequences have identical residues or bases at corresponding positions after sequence alignment. Unless otherwise stated, the identity between a sequence and a reference sequence described in this application refers to the sequence identity determined after a full-length alignment of the sequence to be compared and the reference sequence using a global alignment algorithm. The identity percentage can be calculated by dividing the number of identical residues or bases in the alignment region by the total number of sites in the alignment region and multiplying by 100%. Vacancies generated during alignment are considered as dissimilar sites. The global alignment can be performed using procedures and appropriate parameters recognized in the art.
[0065] Unless otherwise stated, the identity between a sequence and a reference sequence described in this application refers to the sequence identity determined by performing a full-length alignment of the region in the sequence to be compared with the reference sequence. The identity percentage can be calculated by dividing the number of identical residues in the alignment region by the total number of sites in the alignment region and multiplying by 100%. Vacancies generated during alignment are considered as different sites.
[0066] This application uses single-letter or three-letter codes commonly used in the art to represent amino acids. For example, the mutation "R19V" indicates that the arginine R at position 19 of the reference amino acid sequence has been replaced with valine V.
[0067] This application provides a fusion protein that simultaneously possesses GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity, and the fusion protein comprises a first active domain A, a first linker peptide L1, an extended-acting domain B, a second linker peptide L2, and a second active domain C connected sequentially from the N-terminus to the C-terminus.
[0068] Wherein, the first active domain A is a chimeric peptide having GLP-1 receptor agonist activity and GCG receptor agonist activity, and the amino acid sequence of the first active domain A is selected from any one of SEQ ID NO.12 to SEQ ID NO.15;
[0069] The extended-acting domain B comprises the immunoglobulin Fc region or a fragment thereof, or a mutant thereof; for illustrative purposes, the "immunoglobulin Fc region" refers to the constant region portion of the immunoglobulin heavy chain located outside the antigen-binding region. The fragment or mutant of the Fc region retains at least one target function of the Fc region, including FcRn binding, promoting the formation of dimers or other multimers of the fusion protein, prolonging the in vivo half-life, improving the stability of the fusion protein, and binding to Protein A and / or Protein G, among one or more of these functions.
[0070] The second active domain C is FGF21 or an analogue thereof, wherein FGF21 is human FGF21; the amino acid sequence of the FGF21 analogue has greater than or equal to 80% identity with the amino acid sequence of human FGF21 shown in SEQ ID NO. 68, and the FGF21 analogue has FGF21 receptor complex agonist activity. In some embodiments, the identity is greater than or equal to 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, or 97%. Preferably, the identity is greater than or equal to 90%; more preferably, the identity is greater than or equal to 95%.
[0071] This application constructs a single multi-domain fusion protein molecule by combining a chimeric peptide with dual GLP-1 / GCG receptor agonistic activity (first active domain A), an immunoglobulin Fc region (long-acting domain B), and a specifically mutated FGF21 analog (second active domain C) in a specific A-L1-B-L2-C structural configuration. This allows the fusion protein to simultaneously possess three independent pharmacological activities within a single molecule: GLP-1 receptor agonism, GCG receptor agonism, and FGF21 receptor complex agonism. Experimental verification in this application confirms that after the fusion expression of the three domains, the receptor agonistic activity of each domain is simultaneously preserved, and the fusion does not result in the complete loss of the corresponding receptor agonistic activity of any domain. This achieves the integration of GLP-1 / GCG / FGF21 triple agonistic activity into a single fusion protein molecule.
[0072] A "domain" is a region in a biological macromolecule that has a specific structure and independent function, particularly a similar region in a protein. Multiple regions with independent functions constitute a multidomain. In this invention, a multidomain refers to a fusion protein comprising a first active domain A (a chimeric peptide with GLP-1 receptor agonist activity and GCG receptor agonist activity), a long-acting domain B (the Fc region of an immunoglobulin or a fragment thereof, or a mutant thereof), and a second active domain C (FGF21 or an analogue thereof), exhibiting GLP-1R agonist activity, GCGR agonist activity, and FGF21 receptor complex agonist activity. For illustration, a "long-acting domain" refers to a protein, peptide, or its domain that, when linked to an active protein or peptide, can prolong its in vivo half-life, reduce its clearance rate, improve its stability, promote multimer formation, and / or increase its in vivo exposure.
[0073] For clarification, "possessing receptor agonistic activity" refers to the ability of the fusion protein to activate the corresponding receptor and elicit a detectable downstream signaling response. "Simultaneously possessing" all three receptor agonistic activities means that the same fusion protein sample exhibits the corresponding activities in detection systems established for each of the three receptors mentioned above. It is not required that the three activities be measured in the same cells, at the same time, at the same concentration, or in the same detection system, nor is it required that the intensity or EC50 of the three activities be specified. 50 Same. As an explanation, "EC" 50 EC50 refers to the concentration of the analyte required to produce 50% of the maximum measurable biological effect under specific detection conditions. In the same detection system, a lower EC50 value generally indicates a higher potency.
[0074] The term "GLP-1" refers to glucagon-like peptide-1. Glucagon-like peptide-1 (GLP-1) is an incretin produced from proglucagon. It stimulates insulin secretion, protects pancreatic β-cells, inhibits glucagon secretion, gastric emptying, and food intake, leading to weight loss. Liraglutide and semaglutide are GLP-1 analogs and have been approved for the treatment of type 2 diabetes and obesity.
[0075] "GCG" refers to glucagon. Glucagon is a linear polypeptide composed of 29 amino acids, secreted by pancreatic α cells. It promotes glycogenolysis and gluconeogenesis, and along with insulin, it is a crucial factor in determining blood glucose levels. Blood glucose is regulated by both to maintain a stable blood glucose level. Activation of the glucagon receptor has been shown to increase energy expenditure and reduce food intake in both rodents and humans. In treatment, glucagon has been used for acute hypoglycemia; glucagon receptor activation reduces food intake and promotes lipolysis and weight loss in animals and humans.
[0076] "FGF21" refers to natural human fibroblast growth factor 21. Fibroblast growth factor (FGF21) belongs to the FGF21 family of fibroblast growth factors (FGFs). The human FGF21 precursor protein consists of 209 amino acids, with a 28-amino acid signal peptide at its N-terminus; cleavage of the signal peptide forms mature human FGF21, which consists of 181 amino acids. Unless the context otherwise requires, the human FGF21 described in this application refers to mature human FGF21, and the amino acid sequence numbering of FGF21 is based on the sequence shown in SEQ ID NO. 68. FGF21 can promote glucose uptake by adipocytes and enhance insulin sensitivity, and it has no cell division-promoting activity, therefore posing no potential carcinogenic risk. Furthermore, FGF21 also has a good lipid-lowering effect, reducing serum total cholesterol and low-density lipoprotein levels by inhibiting the synthesis of hepatic SREBP-2, thereby alleviating hypercholesterolemia. However, natural FGF21 also has certain drawbacks, such as poor in vitro aggregation and stability, susceptibility to protease hydrolysis, and a short in vivo half-life (30 min in mice and 2-3 h in cynomolgus monkeys). These shortcomings limit the application of FGF21.
[0077] The FGF21 receptor complex refers to the FGFR / β-Klotho receptor complex formed by the fibroblast growth factor receptor and the β-Klotho co-receptor; in some specific detection systems, the FGF21 receptor complex can be the FGFR1c / β-Klotho receptor complex.
[0078] The term "FGF21 analogue" refers to a protein or polypeptide that, based on the human FGF21 amino acid sequence shown in SEQ ID NO. 68, has undergone one or more amino acid substitutions, deletions, or additions, while retaining the agonistic activity of the FGF21 receptor complex. The amino acid sequence of the said FGF21 analogue has greater than or equal to 80% identity with the human FGF21 amino acid sequence shown in SEQ ID NO. 68.
[0079] Specifically, the amino acid sequence of human FGF21 (SEQ ID NO.68) is as follows:
[0080] HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
[0081] The fusion protein in this application has an A-L1-B-L2-C structure. This structure positions the first active domain A at the N-terminus of the fusion protein and the second active domain C at the C-terminus, connected by an extended-acting domain B and a linker peptide.
[0082] The first active domain A is a chimeric peptide with both GLP-1 receptor agonist and GCG receptor agonist activities. This domain mediates the agonist effect of the fusion protein on the GLP-1 and GCG receptors.
[0083] In some preferred embodiments, the amino acid sequence of the first active domain A is shown in SEQ ID NO. 14. Actual activity testing results show that the first active domain A shown in SEQ ID NO. 12 to SEQ ID NO. 15 is suitable for constructing the fusion protein described in this application. Among them, the fusion protein containing SEQ ID NO. 14 exhibits superior overall performance in terms of agonist activity against three receptors and batch-to-batch activity stability; therefore, the first active domain A shown in SEQ ID NO. 14 is determined to be the preferred N-terminal active domain.
[0084] In some embodiments, the fusion protein exists in monomeric and / or polymeric forms, wherein the polymeric form is selected from one or more of dimers, trimers, tetramers, and polymers with a degree of polymerization greater than four. In some embodiments, the polymeric form is formed from two or more fusion protein monomers through covalent and / or non-covalent interactions.
[0085] In some embodiments, the extended-acting domain B may be selected from the complete Fc sequence, partial Fc sequence, or mutant of mammalian IgG1, IgG2, IgG3, or IgG4. The extended-acting domain B can prolong the in vivo half-life of the fusion protein through FcRn-mediated recycling and can promote dimer formation of the fusion protein through natural covalent and / or non-covalent interactions of the Fc region. In some preferred embodiments, the dimer is a homodimer formed mediated by the Fc region carried by the extended-acting domain B. For illustrative purposes, the dimer referred to in this invention is formed through natural non-covalent and covalent interactions of the Fc sequence. Unless otherwise specified, all dimers formed by Fc are homodimers.
[0086] In some embodiments, the amino acid sequence of the extended-acting domain B is selected from SEQ ID NO. 23 or SEQ ID NO. 24. In some preferred embodiments, the amino acid sequence of the extended-acting domain B is as shown in SEQ ID NO. 24. The extended-acting domain B may contain mutated amino acid sequences for regulating Fc region stability, reducing Fc-mediated effector function, improving fusion protein dimer stability, and / or prolonging in vivo half-life, for example, the sequence shown in SEQ ID NO. 24 containing the R192K mutation may be used. The R192K mutation refers to the replacement of arginine R at position 192 of the sequence shown in SEQ ID NO. 24 with lysine K.
[0087] The second active domain C is FGF21 or an analogue thereof, used to mediate the agonistic effect of the fusion protein on the FGF21 receptor complex. In some embodiments, the amino acid sequence of the FGF21 analogue includes one or more mutations relative to the human FGF21 amino acid sequence shown in SEQ ID NO. 68, wherein the amino acid mutations are selected from one or more of R19V, L98R, L146P, S167H, P171A, P171G, R175L, and A180E.
[0088] In some embodiments, the amino acid sequence of the FGF21 analog comprises any of the following sets of mutations relative to the human FGF21 amino acid sequence shown in SEQ ID NO. 68:
[0089] a) R19V, L98R, P171G, and A180E;
[0090] b) R19V, L98R, S167H, P171A and R175L;
[0091] c) R19V, L98R, L146P, P171G and A180E;
[0092] d) R19V, L98R, S167H, P171A and A180E;
[0093] e) L98R, L146P, P171G and A180E.
[0094] In some specific embodiments, the amino acid sequence of the FGF21 analog is shown in SEQ ID NO.25. SEQ ID NO.25 is an FGF21 analog sequence obtained by introducing L98R, L146P, P171G and A180E mutations into the human FGF21 amino acid sequence shown in SEQ ID NO.68.
[0095] In some preferred embodiments, the amino acid sequence of the FGF21 analog is shown in SEQ ID NO.69.
[0096] SEQ ID NO.69:
[0097] HPIPDSSPLLQFGGQVRQVYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRERLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLHMVGASQGRSPSYES
[0098] In some specific embodiments, the first active domain A shown in any one of SEQ ID NO. 12 to SEQ ID NO. 15, the first linker peptide L1 shown in SEQ ID NO. 22, the extended-acting domain B shown in SEQ ID NO. 24, the second linker peptide L2 shown in SEQ ID NO. 22, and the second active domain C shown in SEQ ID NO. 25 can be sequentially linked to obtain the full-length amino acid sequences of the fusion proteins shown in SEQ ID NO. 37 to SEQ ID NO. 40. Actual testing showed that the above fusion proteins possessed GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity. The results indicated that they simultaneously possess all three receptor agonist activities. For illustration, the above fusion proteins share the same extended-acting domain B (SEQ ID NO. 24) and the same second active domain C (SEQ ID NO. 25). Actual testing showed that they all possess FGF21 receptor complex agonist activity, indicating that the FGF21 receptor complex agonist activity is mainly determined by the sequence characteristics of the second active domain C. That is, in the fusion protein of the present invention, the first active domain A and the second active domain C are separated by the extended-acting domain B and the linker peptides L1 and L2. They independently mediate the agonistic effects of the GLP-1 receptor and GCG receptor, as well as the agonistic effect with the FGF21 receptor complex (meaning the presence of one active domain does not lead to the complete loss of function of the other active domain). Therefore, those skilled in the art can reasonably expect that combining the mutant-optimized second active domain C of the present invention (as shown in SEQ ID NO. 69) with the first active domain A sequence in SEQ ID NO. 12–15 will result in a fusion protein that also possesses GLP-1 receptor agonistic activity, GCG receptor agonistic activity, and FGF21 receptor complex agonistic activity.
[0099] In some embodiments, the second active domain C may also employ the human FGF21 amino acid sequence shown in SEQ ID NO. 68. This unmutated natural human FGF21 itself possesses FGF21 receptor complex agonist activity; therefore, when it is used as the second active domain C to link with the first active domain A and the extended-acting domain B to form a fusion protein, it can still confer FGF21 receptor complex agonist activity to the fusion protein.
[0100] In some specific embodiments, the 3G4-10 fusion protein can be obtained by combining the first active domain A shown in SEQ ID NO. 14, the extended domain B shown in SEQ ID NO. 24, and an FGF21 analog containing mutations of R19V, L98R, S167H, P171A, and A180E. In some specific embodiments, the full-length amino acid sequence of the 3G4-10 fusion protein is shown in SEQ ID NO. 70.
[0101] SEQ ID NO.70:
[0102] HSQGTFTSDYSKYLDEKAAQDFVQWLLDGGPSSGAPPPSGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSGGGGSHPIPDSSPLLQFGGQVRQVYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPG VIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRERLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLHMVGASQGRSPSYES
[0103] Based on the known amino acid sequence of the fusion protein shown in SEQ ID NO. 70, those skilled in the art can optimize the coding sequence according to the codon preference of the selected host cell, the type of expression vector, and the requirements of the expression system, thereby obtaining the nucleotide sequence encoding the fusion protein shown in SEQ ID NO. 70.
[0104] The fusion protein shown in SEQ ID NO. 70 exhibited good effects on weight loss, lipid reduction, and liver function improvement in animal models. Therefore, 3G4-10 is the most preferred fusion protein in this application. Other fusion proteins described in this application all adopt the same A-L1-B-L2-C structural form and all contain a first active domain A with GLP-1 receptor / GCG receptor agonistic activity, a long-acting domain B containing the Fc region or its mutant, and a second active domain C with FGF21 receptor complex agonistic activity. Therefore, it is reasonable to expect that other fusion proteins can also produce the same type of technical effects—weight loss, improved lipid metabolism, improved liver function, and relief of metabolic-related diseases—through multi-target agonistic effects on the GLP-1 receptor, GCG receptor, and FGF21 receptor complex.
[0105] The first linker peptide L1 and the second linker peptide L2 in the fusion protein are used to connect adjacent domains and maintain the corresponding spatial conformation and biological activity of the first active domain A, the extended domain B, and the second active domain C. The first linker peptide L1 and the second linker peptide L2 can be the same sequence or different sequences. In some embodiments, both the first linker peptide L1 and the second linker peptide L2 are flexible linker peptides. In some specific embodiments, the amino acid sequences of both the first linker peptide L1 and the second linker peptide L2 are as shown in SEQ ID NO. 22.
[0106] In some embodiments, the fusion protein is a modified fusion protein, and the modification may include chemical modification and / or post-translational modification. In some embodiments, the modification is selected from one or more of glycosylation, phosphorylation, acetylation, amidation, esterification, PEGylation, and disulfide bond formation. The modified fusion protein can simultaneously retain GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity.
[0107] This application also provides an isolated polynucleotide that encodes the above-mentioned fusion protein.
[0108] In some specific embodiments, the nucleotide coding sequence corresponding to the amino acid sequence of the full-length fusion protein is codon-optimized to adapt to the host cell expression system. For example, when using an *E. coli* expression system, codon optimization can utilize codons that are frequently used in the *E. coli* expression system, while avoiding transcription factor binding regions, repetitive sequences, and higher-order RNA structures that may affect expression. For example, for fusion proteins with amino acid sequences as shown in SEQ ID NO. 37–SEQ ID NO. 40, the codon-optimized polynucleotide sequence (fusion protein DNA coding sequence) can be as shown in SEQ ID NO. 58–SEQ ID NO. 61.
[0109] This application also provides a recombinant expression vector that may contain a polynucleotide encoding the aforementioned fusion protein. In some preferred embodiments, the recombinant expression vector further contains a nucleotide sequence encoding a tag for assisting expression and / or purification. In some specific embodiments, the tag is a SUMO tag. The SUMO tag may be attached to the N-terminus of the fusion protein (in the corresponding recombinant vector, the nucleotide sequence encoding the tag is attached to the 5' end of the polynucleotide) for assisting in the expression and purification of the fusion protein. During the isolation and purification process, the SUMO tag can be cleaved by a SUMOase to obtain the target fusion protein.
[0110] This application also provides a host cell, which is a prokaryotic or eukaryotic cell suitable for expressing the fusion protein. In some embodiments, the cell contains exogenous polynucleotides, which contain a nucleotide sequence encoding the aforementioned fusion protein. The polynucleotides may be present on a recombinant expression vector (such as a plasmid) contained within the host cell, or integrated into the genome of the host cell. In some embodiments, the host cell is selected from *E. coli* cells, CHO cells, HEK293 cells, or yeast cells. In some specific embodiments, *E. coli* BL21(DE3) cells may be used as the expression host. In other embodiments, CHO cells, HEK293 cells, or other mammalian cells may be used as the expression host.
[0111] The isolated polynucleotides, recombinant expression vectors, and host cells described above can all be used as biomaterials for preparing the fusion protein described in this application.
[0112] This application also provides a composition containing the above-described fusion protein or biological material; the composition is preferably a pharmaceutical composition. The pharmaceutical composition further contains pharmaceutically acceptable excipients. These pharmaceutically acceptable excipients may include buffers, stabilizers, isotonic modifiers, preservatives, surfactants, excipients, diluents, or combinations thereof.
[0113] In some embodiments, the fusion protein, biomaterial, or composition described in this application can be used as a drug. In some embodiments, the fusion protein, biomaterial, or composition is used to prevent, alleviate, and / or treat diseases, preferably for the prevention, alleviation, and / or treatment of metabolic-related diseases. The prevention, alleviation, and / or treatment may include delaying the onset or progression of the disease, reducing disease symptoms, improving disease-related physiological, biochemical, or pathological indicators, or reducing the risk of disease recurrence. In some specific embodiments, a therapeutically effective amount of the fusion protein, biomaterial, or composition is administered to a subject in need to prevent, alleviate, and / or treat the metabolic-related disease.
[0114] The metabolic-related diseases include diseases, symptoms, pathological states, or clinical manifestations related to metabolic abnormalities. In some embodiments, the metabolic-related diseases are selected from one or more of metabolic dysfunction-related steatohepatitis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, obesity, overweight, type 2 diabetes, hyperlipidemia, hypercholesterolemia, insulin resistance, metabolic syndrome, liver function impairment, hepatic lipid accumulation, and liver fibrosis. In some preferred embodiments, the metabolic-related disease is metabolic dysfunction-related steatohepatitis.
[0115] This application also provides a method for treating metabolic-related diseases, comprising administering a therapeutically effective amount of the above-described fusion protein or the above-described pharmaceutical composition to a subject in need; the specific scope of the metabolic-related diseases is as described above.
[0116] "Therapeutic effective dose" refers to the dosage of a fusion protein, when administered to a subject in need, that is capable of preventing, alleviating, improving, or treating a target disease, condition, or related clinical manifestations. The therapeutic effective dose can be adjusted based on factors such as the subject's species, age, weight, disease type, disease severity, route of administration, frequency of administration, form of the pharmaceutical composition, and the subject's response to the drug. For the fusion protein described in this application, the therapeutic effective dose includes a dosage capable of improving metabolic-related diseases or their related indicators.
[0117] In some embodiments, when treating the aforementioned metabolic-related diseases, the fusion protein or a pharmaceutical composition containing the fusion protein may be administered subcutaneously, intravenously, intramuscularly, intraperitoneally, or by other suitable routes; in some preferred embodiments, the fusion protein or a pharmaceutical composition containing the fusion protein is administered subcutaneously.
[0118] In some embodiments, the fusion protein or pharmaceutical composition containing the fusion protein is administered to the subject at a predetermined dose, with a dosing frequency of once daily, once every two days, once every three days, once weekly, twice weekly, or three times weekly, and a dosing period of 1 to 52 weeks. The dosage and frequency of administration may be adjusted according to the subject's weight, type of disease, and treatment response.
[0119] In some specific embodiments, the preferred 3G4-10 fusion protein of this application can significantly reduce body weight, liver weight, and liver-to-body ratio in MASH model animals, reduce plasma alanine aminotransferase (ALT), plasma aspartate aminotransferase (AST), plasma total cholesterol (TC / T-CHOL / T-CHO), and plasma low-density lipoprotein cholesterol (LDL-C) levels, reduce liver total cholesterol (Liver-CHOL) and liver triglyceride (Liver-TG) content, and improve liver NAS scores. Therefore, the fusion protein can be used to improve hepatic steatosis, hepatocyte ballooning degeneration, liver function impairment, and hepatic and blood lipid metabolism disorders.
[0120] In other embodiments, the fusion protein described in this application or a pharmaceutical composition containing the fusion protein may also be used to promote weight loss, prevent weight gain, reduce appetite, reduce food intake, improve blood glucose levels, improve blood lipid levels, improve insulin resistance, or improve clinical manifestations related to metabolic syndrome.
[0121] This application also provides a method for preparing the above-mentioned fusion protein, comprising the following steps:
[0122] S1. Culture host cells and express the above-mentioned fusion protein in the host cells, or express a fusion precursor protein containing the above-mentioned fusion protein and the tag;
[0123] S2. Isolate and purify the fusion protein from the culture of the host cells;
[0124] In this embodiment, when expressing the fusion precursor protein, the separation and purification includes cleaving the tag to obtain the fusion protein. In some specific embodiments, the tag is a SUMO tag, and the separation and purification includes cleaving the SUMO tag using a SUMOase.
[0125] In some specific embodiments, step S1, the purification of the fusion protein may include cell disruption, inclusion body or precipitate collection, denaturation, renaturation, tag-enzyme digestion, and chromatographic purification. In some embodiments, step S2, the separation and purification further includes one or more of hydrophobic chromatography, hydroxyapatite chromatography, Protein A affinity chromatography, Protein G affinity chromatography, ion exchange chromatography, and molecular sieve chromatography. Since the fusion protein of this application contains an Fc region or a mutant thereof, purification can be performed using the affinity between the Fc region and Protein A or Protein G class packing materials.
[0126] The specific embodiments described above in this application can be understood in conjunction with the subsequent specific embodiments. These specific embodiments can be used to illustrate the screening of candidate first active domain A, recombinant expression and purification of the fusion protein, detection of the agonistic activity of the GLP-1 receptor / GCG receptor / FGF21 receptor complex, optimization of the FGF21 analogue segment, and efficacy evaluation of the 3G4-10 fusion protein in MASH model animals.
[0127] The technical solution of this application has the following characteristics:
[0128] This application successfully constructed a fusion protein through sequence design and optimization. This fusion protein possesses three independent pharmacological activities within the same molecule: GLP-1 receptor agonist, GCG receptor agonist, and FGF21 receptor complex agonist.
[0129] Actual activity tests show that in the multi-domain fusion protein obtained in this application, each domain can function relatively independently (meaning that the presence of one domain does not lead to the complete loss of function of another domain), but the specific sequence of one domain may affect the activity level of another domain. This phenomenon indicates that simply tandemly combining known functionally independent active fragments does not necessarily yield a target fusion protein with stable activity and uniform overall performance.
[0130] Therefore, this application systematically screened and compared the activity of multiple candidate first active domain A sequences, and obtained the first active domain A sequence with the best overall activity. Based on this, addressing the inherent defects of natural FGF21, such as easy aggregation in vitro, easy degradation by proteases, and short half-life in vivo, this application performed combinatorial mutations on specific sites in the FGF21 amino acid sequence, and obtained the second active domain C sequence, which significantly increased the proportion of the target protein's main band in the CHO cell expression system and exhibited superior activity compared to human FGF21 without mutations. This resulted in a fusion protein with high GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity. Given the interaction of the aforementioned domains, the fusion protein obtained in this application simultaneously possesses excellent GLP-1, GCG, and FGF21 agonist activities. In the B6-Alms1-del mouse MASH model, it simultaneously achieved multi-dimensional therapeutic effects, including weight loss, improvement in liver and plasma lipid metabolism, improvement in liver function damage, and improvement in liver steatosis and ballooning degeneration scores. Furthermore, many efficacy indicators were superior to single-target positive control drugs. This multidimensional synergistic therapeutic effect is difficult to achieve simultaneously by existing drugs with only single or dual receptor agonist activity, demonstrating the beneficial technical effects of the triple agonist fusion protein described in this application compared to existing single-target or dual-target drugs.
[0131] The following description, in conjunction with specific embodiments, provides further details.
[0132] Example 1: Overall structural design of the fusion protein
[0133] This example illustrates the structural design of fusion proteins.
[0134] This fusion protein is a multi-domain fusion protein, requiring simultaneous GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity. In its design, the amino acid sequences of the human GLP-1 / GCG chimeric peptide, the Fc region of IgG4, and the FGF21 protein were referenced, with linker peptides added between them. This results in a fusion protein containing, from the N-terminus to the C-terminus, a first active domain A, a first linker peptide L1, a long-acting domain B, a second linker peptide L2, and a second active domain C, i.e., an A-L1-B-L2-C structural form.
[0135] The first active domain A is a chimeric peptide possessing both GLP-1 receptor agonist activity and GCG receptor agonist activity. The amino acid sequence of the first active domain A can be selected from any one of SEQ ID NO.1 to SEQ ID NO.21. Table 1 shows the amino acid sequence information of the candidate first active domain A.
[0136] Table 1
[0137]
[0138] The extended-acting domain B contains the immunoglobulin Fc region or a mutant thereof. The extended-acting domain B can be selected from the complete Fc sequence, partial Fc sequence, or mutant thereof of mammalian IgG1, IgG2, IgG3, or IgG4. In this embodiment, the extended-acting domain B uses the amino acid sequence shown in SEQ ID NO. 24, which is an excerpt from a mutant sequence of human IgG4 Fc, i.e., a partial Fc sequence. In other embodiments, the amino acid sequence of the extended-acting domain B may also be as shown in SEQ ID NO. 23.
[0139] The second active domain C is an FGF21 analog. The amino acid sequence of the FGF21 analog should have greater than or equal to 80% identity with the human FGF21 amino acid sequence shown in SEQ ID NO. 68, and possess FGF21 receptor complex agonist activity. Specifically, in this embodiment, the amino acid sequence of the FGF21 analog used is shown in SEQ ID NO. 25. This sequence is obtained by introducing L98R, P171G, and A180E mutations based on the sequence shown in SEQ ID NO. 68, and has greater than 95% identity with the sequence shown in SEQ ID NO. 68. In other embodiments, the human FGF21 amino acid sequence shown in SEQ ID NO. 68, or other FGF21 analog sequences obtained by further mutations based on the human FGF21 amino acid sequence, may also be used (the final FGF21 analog may contain one or more mutations among R19V, L98R, L146P, S167H, P171A, P171G, R175L, and A180E).
[0140] The first linker peptide L1 and the second linker peptide L2 are used to connect adjacent structural domains and maintain the corresponding spatial conformation and biological activity of the first active structural domain A, the extended structural domain B, and the second active structural domain C. In this embodiment, the amino acid sequences of the first linker peptide L1 and the second linker peptide L2 are both as shown in SEQ ID NO. 22.
[0141] The above sequences are combined and sequentially linked to the first active domain A (any one of SEQ ID NO. 1 to 21), the first linker peptide L1 (SEQ ID NO. 22), the extended domain B (SEQ ID NO. 24), the second linker peptide L2 (SEQ ID NO. 22), and the second active domain C (SEQ ID NO. 25), finally obtaining the 21 full-length amino acid sequences shown in SEQ ID NO. 26 to SEQ ID NO. 46.
[0142] The nucleotide coding sequences corresponding to the above 21 full-length amino acid sequences were modified. Codons were selected based on their high frequency of use in the *E. coli* expression system, while avoiding transcription factor binding regions, repetitive sequences, and higher-order RNA structures that might affect expression. The DNA coding sequences of the fusion protein obtained after codon optimization are shown in SEQ ID NO.47–SEQ ID NO.67. Then, a nucleotide sequence corresponding to the SUMO tag was added to the 5' end of the sequences shown in SEQ ID NO.47–SEQ ID NO.67 to obtain the fusion protein coding sequence with the SUMO tag. In this sequence, the SUMO tag is directly linked to the polynucleotide encoding the fusion protein. The SUMO tag itself provides the structure required for SUMO enzyme recognition and cleavage; the SUMO tag is removed during the final protein purification process.
[0143] Specifically, the amino acid sequence (SEQ ID NO.71) of the SUMO tag used in this embodiment is as follows:
[0144] MGHHHHHHGGSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGG
[0145] The nucleotide sequence encoding this SUMO tag (SEQ ID NO.72) is as follows:
[0146] ATGGgccaccaccatcatcacggtggcagcgacagtgaagtgaaccaggaagcgaaaccggaggtcaaaccggaagtgaaaccggaaacccatattaacctgaaagtgagcgacggcagcagtgaaattttcttcaaaattaagaaaaccacgccgc tgcgccgtctgatggaagcgtttgcgaaacgccagggcaaagaaatggatagcctgcgctttctgtatgatggcattcgcattcaggcggatcagaccccggaagatctggatatggaagacaacgatattatcgaagcccatcgcgaacagatggcggt
[0147] Primers were designed and the coding sequence of the fusion protein with the SUMO tag was amplified. NcoI and NotI restriction sites were introduced at both ends of the sequence. The amplified products were digested with NcoI and NotI and then ligated with pET28a plasmid (purchased from ThermoFisher). The digested fragments were ligated with T4 DNA ligase. The resulting recombinant plasmid was transformed into Escherichia coli DH5α strain and cultured overnight at 37°C in an inverted manner. The following day, a subset of clones were selected for PCR identification and sequencing, resulting in the successful construction of 21 recombinant plasmids (the plasmid names are referenced in Table 1): 21G1-4F-pET28a, 21G2-4F-pET28a, 22G1-4F-pET28a, 22G2-4F-pET28a, 2G5-4F-pET28a, 2G6-4F-pET28a, 2G7-4F-pET28a, 2G8-4F-pET28a, and 2G9-4F-pET28a. , 2G10-4F-pET28a, 3G1-4F-pET28a, 3G2-4F-pET28a, 3G3-4F-pET28a, 3G4-4F-pET28a, 3G5-4F-pET28a, 3G6-4F-pET28a, 3G7-4F-pET28a, 3G8-4F-pET28a, 3G9-4F-pET28a, 3G10-4F-pET28a, and 3G11-4F-pET28a.
[0148] The recombinant plasmids described above were transformed into *E. coli* strain BL21(DE3). A subset of clones were selected for expression verification. SDS-PAGE was used to verify the expression of the recombinant proteins, resulting in 21 recombinant engineered strains: 21G1-4F-pET28a-BL21(DE3), 21G2-4F-pET28a-BL21(DE3), 22G1-4F-pET28a-BL21(DE3), 22G2-4F-pET28a-BL21(DE3), 2G5-4F-pET28a-BL21(DE3), 2G6-4F-pET28a-BL21(DE3), 2G7-4F-pET28a-BL21(DE3), 2G8-4F-pET28a-BL21(DE3), 2G9 ...9-4F-pET28a-BL21(DE3), 2G9-4F-pET28a-BL21(DE3), 2G9-4F-pET28a-BL21(DE3), 2G9-4F-pET28a-BL21(DE3), 2G9-4F-pET28a E3), 2G10-4F-pET28a-BL21 (DE3), 3G1-4F-pET28a-BL21 (DE3), 3G2-4F-pET28a-BL21 (DE 3), 3G3-4F-pET28a-BL21 (DE3), 3G4-4F-pET28a-BL21 (DE3), 3G5-4F-pET28a-BL21 (DE3) , 3G6-4F-pET28a-BL21 (DE3), 3G7-4F-pET28a-BL21 (DE3), 3G8-4F-pET28a-BL21 (DE3), 3 G9-4F-pET28a-BL21 (DE3), 3G10-4F-pET28a-BL21 (DE3), and 3G11-4F-pET28a-BL21 (DE3).
[0149] The SDS-PAGE results of the above recombinant engineered bacteria showed that, except for 21G1-4F-pET28a-BL21(DE3), there were clear heterologous protein expression bands in the other E. coli cultures, which were consistent with the theoretical molecular weight of SUMO-21G2-4F to SUMO-3G11-4F (approximately 62.5 kDa), indicating that the above proteins were effectively expressed.
[0150] Example 2: Fermentation Expression Test of Recombinant Engineered Bacteria
[0151] The 20 strains that successfully expressed the aforementioned heterologous proteins, preserved in glycerol tubes, were inoculated into LB medium at a ratio of 1:1000 (v / v) and cultured in shake flasks for 16-24 hours. During the cell proliferation phase, the shake-flask culture was inoculated into fermentation medium at a ratio of 1:20 (v / v). Dissolved oxygen levels were maintained above 20% by adjusting the rotation speed, tank pressure, and aeration rate, allowing *E. coli* cells to grow for 3-4 hours. During the induction phase, IPTG was added to maintain dissolved oxygen levels above 20%. Fermentation was terminated after 4 hours of induction, and the fermented cells were collected by centrifugation for subsequent purification.
[0152] Fermentation cells from different time points were subjected to SDS-PAGE analysis. For example... Figure 1 The results show the identification of 3G4-4F-pET28a-BL21(DE3), with lanes 1 to 5 representing the test samples of the recombinant strain 3G4-4F-pET28a-BL21(DE3) before fermentation induction, at 5 hours, 10 hours, 15 hours, and 20 hours, respectively. Figure 1 It can be seen that the expression level of SUMO-3G4-4F protein increases continuously with the extension of induction time, and the expression level of the target protein accounts for more than 20% of the total bacterial protein, which meets the requirements of large-scale production. The expression trend of other bacterial strains is similar to that of 3G4-4F-pET28a-BL21(DE3).
[0153] Example 3 Purification of the fusion protein
[0154] The fermentation cells collected in Example 2 were added to Tris buffer at pH 7.5 and homogenized three times at 900 bar using a homogenizer. The precipitate was collected by centrifugation at 15000g for 30 min. The precipitate was washed three times with Tris buffer at pH 8.0 and then dispersed in Tris-urea denaturing buffer (50 mM Tris, 8 M urea, 5-10 mM dithiothreitol, pH 8.0-8.5) to dissolve the precipitate and obtain a denatured protein solution. The denatured protein solution was then slowly added dropwise to Tris refolding buffer (50 mM Tris, 1 M urea, 0.1-0.5 M arginine, 2 mM cysteine, 0.4 mM cysteine, pH 8.0-9.0) to refold the protein, obtaining a refolded protein dispersion.
[0155] The refolded protein dispersion was digested with SUMO enzyme at a mass ratio of enzyme:refolded protein dispersion = 1:(2000-10000) and incubated overnight at 4°C to remove the N-terminal SUMO tag and obtain the target fusion protein.
[0156] The following day, the refolded protein dispersion after enzyme digestion was purified using a hydrophobic chromatography column. Specifically, NaCl was added to 1-2 L of the enzyme-digested refolded protein dispersion to bring the final NaCl concentration to 0.5-1 M. The resulting sample was then loaded onto a 50 mL hydrophobic chromatography column. After loading, the column was eluted with Tris buffer containing NaCl to remove unbound or weakly bound impurities; subsequently, it was eluted with Tris buffer at pH 8.0, and the eluent containing the target fusion protein was collected.
[0157] The eluent was further purified by CHT chromatography. Specifically, NaCl was added to 50-100 mL of the eluent to bring the final NaCl concentration to 0.1 mol / L, and then the sample was loaded onto a CHT column. After loading, the sample was eluted with Tris buffer (pH 8.0) and then eluted with PB buffer (pH 7.5). The eluent of the target fusion protein was collected to obtain a high-purity, low-endotoxin target fusion protein. SDS-PAGE results of some fusion proteins are shown below. Figure 2 As shown, lanes 1 to 4 are hydrophobic chromatography samples of 21G2-4F, 22G1-4F, 3G3-4F, and 3G4-4F, respectively, and lanes 5 to 8 are CHT chromatography purified samples of 21G2-4F, 22G1-4F, 3G3-4F, and 3G4-4F, respectively. The electrophoretic purity of the above samples is greater than 85%, which can be used for subsequent activity confirmation.
[0158] The aforementioned fusion protein retains the conventional characteristics of the Fc region, such as its in vivo half-life being extended by binding to the Fc receptor (FcRn), and its high affinity and specificity binding to Protein A or Protein G class packing materials during the separation and purification process, enabling efficient purification of the target protein. In some other embodiments, the purification process may also employ Protein A affinity chromatography to replace or supplement the aforementioned hydrophobic chromatography step.
[0159] Example 4: In vitro cell activity analysis of recombinant multi-domain fusion protein
[0160] The fusion protein obtained after purification in Example 3 was subjected to in vitro activity assays, including GLP-1 receptor agonist activity assay, GCG receptor agonist activity assay, and FGF21 receptor complex agonist activity assay.
[0161] The activities of GLP-1 and GCG were determined using an in vitro cell activity assay, specifically a luciferase reporter gene assay, based on the principle that GLP-1R and GCG activation can activate the downstream cAMP pathway. The activity of FGF21 and its analogues was detected by co-transfecting FGF21R and β-klotho into a 293 cell line (GM-C19834, Jiman Biotechnology (Shanghai) Co., Ltd.), and then detecting the fluorescence changes caused by the transduction signal after the FGF21 agonist binds to the two receptors.
[0162] The method for detecting GLP-1 in vitro activity was as follows: HEK293 cells expressing GLP-1 receptor and CRE-luciferase (Nanjing Genscript Biotech Co., Ltd., catalog number M00562) were used for the assay. Cells were seeded in 96-well plates at a density of 20,000 cells / well / 50 μL. The fusion protein to be tested was serially diluted 5-fold from a certain concentration to 11 gradients in DMEM complete medium, and 50 μL was added to each well. The plates were incubated at 37℃ and 5% CO2 for 3 h. After equilibration at room temperature for 10 minutes, 100 μL of luciferase reagent (PerkinElmer, catalog number 6066769) was added to each well. The plates were protected from light for 3 minutes, and after mixing by pipetting 10 times, 100 μL was transferred to a white detection plate. The fluorescence readings were detected using a chemiluminescence analyzer. A curve was plotted with concentration on the x-axis and fluorescence reading on the y-axis, and the EC50 was calculated. 50 EC 50 (Concentration for 50% of maximal effect) refers to the concentration of a drug or substance required to stimulate half of its corresponding biological response. EC 50 The lower the value, the stronger the stimulating or stimulating ability of the drug or substance, and the better the expected efficacy.
[0163] For the in vitro activity assay of GCG, CHO-K1 cells expressing GCG receptor and CRE-luciferase (Nanjing Genscript Biotech Co., Ltd., catalog number M00890) were used, and the procedure was the same as that for the GLP-1 assay.
[0164] FGF21 in vitro activity assay: HEK293 cells expressing the FGF21 receptor complex and Luciferase reporter gene were constructed by co-transfecting the FGF21 receptor (FGFR1c) and co-receptor β-klotho into the cells (GM-C19834, Jiman Biotechnology (Shanghai) Co., Ltd.). This was used to evaluate the FGF21 receptor complex agonistic activity of the fusion protein. For assay, the above-mentioned cells were seeded in 96-well plates at a density of 15,000 cells / well / 100 μL and cultured at 37°C and 5% CO2 for 24 h. The fusion protein to be tested was serially diluted 3-fold (9 gradients) in DMEM medium containing 1% FBS from a certain concentration. After discarding the medium in the wells, the serial dilution buffer of the fusion protein to be tested was added to each well (100 μL), and the plates were cultured at 37°C and 5% CO2 for 24 h. Subsequent fluorescence detection procedures were the same as for the GLP-1 in vitro activity assay, with a light-protected time of 5 minutes. EC50 was calculated. 50 .
[0165] The in vitro activity data of each fusion protein are shown in Table 2. Figure 3 Semaglutide, listed in the table, is a GLP-1 receptor agonist. NA indicates not detected, and ND indicates not detected.
[0166] Table 2
[0167]
[0168] The data in the table show that although all 21 candidate sequences tested were structurally similar GLP-1 / GCG dual-agonist chimeric peptides, the EC50 values of their corresponding fusion proteins exhibited a wide range of GLP-1 receptor agonist activity, with the lowest value (3G9-4F, 0.006605 nM) differing from the highest value (2G9-4F, 12.89 nM) by nearly 2000 times. A comprehensive comparison of the stability of activity across different batches of samples... Figure 3 (Mean error line), confirming that the 3G4-4F activity data is the best, that is, the fusion protein with the first active domain A as SEQ ID NO.14 has the best overall performance.
[0169] Furthermore, the second active domain C of the fusion proteins in the table has the same sequence. The detection results of the fusion proteins subjected to FGF21 receptor complex agonist activity assays all showed FGF21 receptor complex agonist activity. This indicates that the FGF21 receptor complex agonist activity is mainly determined by the sequence characteristics of the second active domain C, and the specific sequence selection of the first active domain A does not lead to the loss of function of the second active domain.
[0170] However, the first active domain A still has some influence on the function of the second active domain C. As shown in Table 2, when the sequence of the first active domain A of the fusion protein is different, the agonist activity of the FGF21 receptor complex in the resulting fusion protein is affected by EC. 50 The values ranged from 2.083 to 3.078 nM, with the highest value being approximately 47.8% higher than the lowest. This indicates that for this type of multi-domain fusion protein, simply tandemly combining the individual functional active domains cannot guarantee a target molecule with stable activity and uniform overall performance. The sequence selection of the first active domain A still affects the agonistic activity of the FGF21 receptor complex mediated by the second active domain C to some extent. Therefore, it is necessary to continuously screen and optimize the specific sequences, arrangements, and connection methods of each domain based on actual activity detection data to obtain multi-domain fusion proteins with stable activity and excellent overall performance.
[0171] Example 5 Sequence optimization of fusion protein
[0172] The purpose of this embodiment is to further optimize the FGF21 region sequence of the fusion protein obtained in Example 3, in order to improve its activity and the proportion of the target protein's main band in the CHO expression system. This embodiment designed 20 FGF21 region sequences (FGF21 analog sequences), as shown in Table 3. The Fc region sequence referred to as "Fc region R192K" in the table is the sequence shown in SEQ ID NO. 24, meaning that the arginine R at position 192 in the sequence shown in SEQ ID NO. 24 has been replaced with lysine K.
[0173] Table 3
[0174]
[0175] For illustrative purposes, the sequences of the first linker L1 and the second linker L2 after the replacement in 3G4-8 are both: APAPAPAPAPAPAPAPAPAPAP, and the nucleotide sequence encoding them is: GCTCCTGCCCCAGCACCCGCTCCCGCACCTGCCCCTGCTCCAGCCCCAGCTCCTGCACCC.
[0176] Based on the above-mentioned mutated sequence, a recombinant plasmid was constructed, and transient transfection expression was performed using CHO-K1 cells. The expression results are as follows: Figures 4-6 As shown, the lanes correspond to those in Table 3 above. Figure 4 Lanes 1-9 show the detection results of fusion proteins expressed by 3G4-1-9 molecules via transient transtransduction in CHO. Figure 5 Lanes 1 to 9 are 3G4-10 (lane 1), 2G5-1 (lane 2), and 2G5-2 (lane 3), respectively. The results of the detection of fusion proteins expressed by CHO transient transtransduction of 2G5-2 (lane 4) and 3G4-F1~F5 (lanes 5~9), which were synthesized by others at the request of others. Figure 6 Lanes 1-5 were 3G4-4F (the purified fusion protein from Example 3), 3G4-D1-D3, the control negative molecule EGFP transiently expressed in CHO, and the detection results of blank cell supernatant. Figures 4-6 The left side of the image shows the SDS-PAGE results, and the right side shows the WB results. The right-hand image is used to confirm the presence of degradation molecules. Based on the electrophoresis and WB results, it was confirmed that the expression products of sequences 2G5-2, 3G4-5, 3G4-6, 3G4-9, and 3G4-10 had a better proportion of the main band, indicating less protein degradation.
[0177] It is worth noting that, Figure 4The results showed that the FGF21 mutation combination used in 3G4-7 was exactly the same as that in 3G4-6, except for the additional introduction of the R192K mutation in the Fc region. However, the proportion of the main band in CHO cells transiently expressed was not better than that in 3G4-6, indicating that the effect of adding other seemingly reasonable modifications on the basis of known effective mutation combinations cannot be predicted in advance based on existing knowledge. Similarly, 3G4-8 changed the linker peptide sequence while keeping the FGF21 mutation combination unchanged to investigate whether the linker peptide was a factor affecting the purity of protein expression. However, the proportion of the main band was not improved compared with similar molecules that retained the linker peptide shown in SEQ ID NO. 22, indicating that the linker peptide sequence is not a key factor affecting the proportion of the main band of the target protein, and the linker peptide sequence shown in SEQ ID NO. 22 is suitable for the construction of the fusion protein described in this application.
[0178] The expression product of the above sequence was further purified, and the FGF21 receptor complex agonist activity of the purified product was detected according to the method described in Example 4. Partial activity test results are shown in Table 4. In the table, the test results equal the reference EC value. 50 EC value of the test sample 50 The reference standard (positive control) is monomeric recombinant human FGF21 protein (with activity).
[0179] Table 4
[0180]
[0181] The results showed that the FGF21 receptor complex of 3G4-10 exhibited the best agonistic activity, with a relative activity 1.70 times that of the reference sample.
[0182] The FGF21 sequence (second active domain C) corresponding to 3G4-10 is shown in SEQ ID NO. 69, and its identity with the sequence shown in SEQ ID NO. 68 is greater than 95%. Replacing the second active domain C in the 3G4-4F molecule (first active domain A is SEQ ID NO. 14, and extended-acting domain B is SEQ ID NO. 24) in Example 3 with the FGF21 analog shown in SEQ ID NO. 69, and recombining them according to the A-L1-B-L2-C structure, yields the fusion protein 3G4-10, whose full-length amino acid sequence is shown in SEQ ID NO. 70.
[0183] Furthermore, as shown in Tables 3 and 4, 2G5-2 and 3G4-10 have the same second active domain C sequence, while the first active domain A sequences are different (3G4-10 corresponds to SEQ ID NO. 14, and 2G5-2 corresponds to SEQ ID NO. 5). This result indicates that the sequence shown in SEQ ID NO. 69, when combined with different first active domains A, all exhibit clearly detectable agonist activity of the FGF21 receptor complex (although there are differences in activity), suggesting that the optimized FGF21 segment scheme has a certain degree of universality.
[0184] Example 6: In vivo pharmacodynamic analysis of the fusion protein in animals
[0185] The 3G4-10 protein used in the in vivo efficacy experiment in this embodiment is the fusion protein shown in SEQ ID NO.70.
[0186] The purpose of this embodiment is to study the pharmacological effects of subcutaneous injection of 3G4-10 protein (SEQ ID NO.70) in the B6-Alms1-del mouse MASH model and to evaluate whether the protein has a comprehensive metabolic improvement effect such as MASH relief, liver function protection, weight loss, and lipid reduction.
[0187] Mice (purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.) were introduced into the animal facility and, upon reaching 18-19 weeks of age, were fasted for 5-6 hours before blood was collected. Plasma was separated, and liver function (ALT, AST) and blood lipids (TC, TG, LDL-C, HDL-C) were measured. B6-Alms1-del mice were randomly divided into three groups of 8 mice each, totaling 24 mice: the 3G4-10 group, the positive control drug group (Efruxifermin, MCE, catalog number HY-P99930), and the solvent group (PBS buffer, Vehicle, Maixin Biotechnology, batch number 25042101). The day of grouping was defined as D-1.
[0188] Dosing began on day 0. The positive control drug and the fusion protein 3G4-10 were both administered at a dose of 30 nmol / kg (the amount of the fusion protein was calculated based on the amount of the dimer). Dosing frequency was Q3D for both groups. The solvent group received an equal volume of solvent. The dosing cycle was 6 weeks (the 3G4-10 group was discontinued three times due to excessive weight loss in mice, with the last four doses being 1 / 3 of the original dose). During the efficacy period, mouse weight was measured every 3 days, and 24-hour food intake was measured twice weekly.
[0189] Six weeks after drug administration, on Day 42, the mice were weighed and then fasted for 5-6 hours.
[0190] (1) Collect blood and separate plasma. One copy is used for liver function (ALT, AST) and blood lipid four items (CHOL, TG, LDL-C, HDL-C), and the other copy is stored at -80℃ as a backup.
[0191] (2) The mice were sacrificed, and the livers were weighed, photographed, and the liver index was calculated.
[0192] (3) One sample each from the left, middle and right lobes of the liver was taken, fixed with 4% PFA, dehydrated, embedded in paraffin, stained with HE and PSR, and NAS and fibrosis scores were calculated.
[0193] For detailed mouse weight data, please refer to Figure 7 The left side of the figure shows the body weight values, and the right side shows the rate of change in body weight relative to day 0; detailed data on CHOL and TG in mouse liver homogenate can be found in [link to graph]. Figure 8 Detailed mouse blood biochemical data can be found in [link to relevant documentation]. Figure 9 (T-CHO in the figure refers to TC, total plasma cholesterol); See mouse liver NAS data for details. Figure 10 .
[0194] The test results showed that in the B6-Alms1-del mouse MASH model, subcutaneous injection of 3G4-10 (30 nmol / kg) Q3D for 6 weeks significantly reduced body weight, liver weight and liver-to-body ratio, significantly reduced plasma ALT, AST, CHOL, LDL-C levels, and reduced liver CHOL (Liver-CHOL) and TG (Liver-TG) content; and significantly improved liver NAS score (Steatosis Grade Score, Ballooning). The improvement effect on liver fibrosis was not reflected due to the low degree of fibrosis in the model itself.
[0195] In summary, 3G4-10 can significantly improve the liver pathological features of the B6-Alms1-del mouse MASH model, and also has the effects of weight reduction, improvement of liver and blood lipid metabolism disorders, and improvement of liver function damage. Moreover, most of the improvement effects are better than those of single-target positive control.
[0196] Based on the above efficacy results, it is expected that this fusion protein can be used not only to prevent, alleviate or treat metabolic dysfunction-associated steatohepatitis (MASH), but also to prevent and / or treat other metabolic-related diseases such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), obesity, overweight, type 2 diabetes, hyperlipidemia, hypercholesterolemia, insulin resistance, metabolic syndrome, liver function impairment, hepatic lipid accumulation and liver fibrosis.
[0197] In other embodiments, the fusion protein of the present invention can also be used to promote weight loss or prevent weight gain, in which case a therapeutically effective amount of the fusion protein or a drug containing the fusion protein may be administered to the subject in need.
[0198] The above embodiments are merely illustrative of the principles and effects of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by those skilled in the art without departing from the spirit and technical concept disclosed in the present invention should still be covered by the claims of the present invention.
Claims
1. A fusion protein, characterized in that, The fusion protein simultaneously possesses GLP-1 receptor agonist activity, GCG receptor agonist activity, and FGF21 receptor complex agonist activity, and the fusion protein comprises a first active domain A, a first linker peptide L1, an extended-acting domain B, a second linker peptide L2, and a second active domain C connected sequentially from the N-terminus to the C-terminus. Wherein, the first active domain A is a chimeric peptide having GLP-1 receptor agonist activity and GCG receptor agonist activity; the amino acid sequence of the first active domain A is selected from any one of SEQ ID NO.12 to SEQ ID NO.15; The extended-acting domain B contains the immunoglobulin Fc region or a fragment thereof, or a mutant thereof; The second active domain C is FGF21 or an analogue thereof, wherein FGF21 is human FGF21, and the FGF21 analogue has greater than or equal to 80% identity with the amino acid sequence of human FGF21 and has FGF21 receptor complex agonist activity.
2. The fusion protein according to claim 1, characterized in that, The extended-acting domain B is selected from the complete Fc sequence, partial Fc sequence or mutant of mammalian IgG1, IgG2, IgG3 or IgG4; preferably, the amino acid sequence of the extended-acting domain B is as shown in SEQ ID NO.23 or SEQ ID NO.
24.
3. The fusion protein according to claim 1, characterized in that, The FGF21 sequence is SEQ ID NO.68; preferably, the FGF21 analogue includes one or more of the following mutations relative to the human FGF21 amino acid sequence shown in SEQ ID NO.68: R19V, L98R, L146P, S167H, P171A, P171G, R175L and A180E.
4. The fusion protein according to any one of claims 1-3, characterized in that, The amino acid sequence of the FGF21 analog contains any of the following groups of mutations relative to the human FGF21 amino acid sequence shown in SEQ ID NO. 68: a) R19V, L98R, P171G, and A180E; b) R19V, L98R, S167H, P171A and R175L; c) R19V, L98R, L146P, P171G and A180E; d) R19V, L98R, S167H, P171A and A180E; e) L98R, L146P, P171G and A180E.
5. The fusion protein according to claim 1, characterized in that, The amino acid sequences of the FGF21 analogues are shown in SEQ ID NO.25 or SEQ ID NO.69; And / or, the amino acid sequences of the first linker peptide L1 and the second linker peptide L2 are both as shown in SEQ ID NO.
22.
6. The fusion protein according to claim 5, characterized in that, The amino acid sequence of the first active domain A is shown in SEQ ID NO.14, and the amino acid sequence of the extended domain B is shown in SEQ ID NO.
24.
7. The fusion protein according to claim 1, characterized in that, The amino acid sequence of the fusion protein is shown in any one of SEQ ID NO.37 to SEQ ID NO.40 or SEQ ID NO.
70.
8. A biomaterial, characterized in that, The biomaterial is selected from any one of the following: 1) An isolated polynucleotide, said polynucleotide comprising a nucleotide sequence encoding the fusion protein of any one of claims 1-7; 2) A recombinant expression vector comprising the polynucleotide described in 1); preferably, the recombinant expression vector further comprises a nucleotide sequence of a tag for assisting expression and / or purification; more preferably, the tag is a SUMO tag; 3) Host cell, wherein the host cell contains the polynucleotide described in 1) or the recombinant expression vector described in 2); preferably, the host cell is selected from Escherichia coli cells, CHO cells, HEK293 cells or yeast cells.
9. The application of the fusion protein according to any one of claims 1-7, or the biomaterial according to claim 8, characterized in that, The application is for the preparation of drugs for the prevention and / or treatment of metabolic-related diseases; Preferably, the metabolic-related disease is selected from one or more of the following diseases: metabolic dysfunction-related steatohepatitis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, obesity, overweight, type 2 diabetes, hyperlipidemia, hypercholesterolemia, insulin resistance, metabolic syndrome, liver dysfunction, hepatic lipid accumulation, and liver fibrosis.
10. A method for treating metabolic-related diseases, characterized in that, Includes administering a therapeutically effective amount of the fusion protein according to any one of claims 1 to 7 to subjects in need; Preferably, the metabolic-related disease is selected from one or more of the following diseases: metabolic dysfunction-related steatohepatitis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, obesity, overweight, type 2 diabetes, hyperlipidemia, hypercholesterolemia, insulin resistance, metabolic syndrome, liver function impairment, hepatic lipid accumulation, and liver fibrosis; more preferably, the metabolic-related disease is metabolic dysfunction-related steatohepatitis.
